PB
PBM.US Psyence Biomedical Ltd. Common Shares
- Market cap
- USD 12.0M
- P/E
- -
- P/B
- 0.71x
- ROE
- -40.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is PBM.US undervalued?
Graham numberThe Graham number of Psyence Biomedical Ltd. Common Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Psyence Biomedical Ltd. Common Shares fundamental analysis
No fundamental analysis for Psyence Biomedical Ltd. Common Shares yet.
Psyence Biomedical Ltd. Common Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Full company profilePsyence Biomedical Ltd. Common Shares financial statements
Psyence Biomedical Ltd. Common Shares annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -240.00 | -4.27K | -5.27K |
| Operating Income | -334K | -4.38M | -2.75M | -3.66M | -6.24M |
| EBITDA | 10.6M | 10.8M | -51.1M | 1.03M | -6.92M |
| Net Income | 8.23M | 8.01M | -51.2M | 1.01M | -6.94M |
| EPS | 0.25 | 0.25 | -7.85 | 1.78 | -13 |
| Balance Sheet | |||||
| Total Assets | 327M | 259M | 1.13M | 7.32M | 17.6M |
| Total Liabilities | 16.4M | 14.3M | 12.1M | 594K | 623K |
| Shareholders' Equity | 237M | 245M | -11.0M | 6.72M | 16.9M |
| Cash & Short-term Investments | 432K | 16.0K | 763K | 6.14M | 7.44M |
| Total Debt | - | 685K | 10.4M | - | - |
| Cash Flow | |||||
| Operating Cash Flow | -1.07M | -2.15K | -2.95M | -3.73M | -8.14M |
| Capital Expenditure | 0.00 | 0.00 | 5.73K | 9.88K | 500K |
| Free Cash Flow | -839K | -520K | -2.95M | -3.74M | -8.64M |
| Ratios | |||||
| ROE | 3.5% | 3.3% | - | 15.1% | -40.9% |
| ROA | 2.5% | 3.1% | -4,518.7% | 13.8% | -39.5% |
| Debt to Equity | - | 0.00x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Psyence Biomedical Ltd. Common Shares dividends
Psyence Biomedical Ltd. Common Shares has not paid dividends in the last 5 fiscal years.
Last stock split: 16:100 on Feb 2, 2026.
Who owns Psyence Biomedical Ltd. Common Shares
- Insiders 2.97%
- Institutions 12.77%
- Public & others 84.26%
- Shares outstanding 3.81M
- Free float 1.11M
Top funds holding PBM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AdvisorShares Psychedelics ETF | 258K | 6.77% | 0.00% | Oct 2026 |
Top institutions holding PBM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Parallel Advisors, LLC | 151K | 3.97% | 0.00% | Jun 2026 |
| AdvisorShares Investments, LLC | 122K | 3.20% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 37.8K | 0.99% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 30.4K | 0.80% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 15.1K | 0.40% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 11.7K | 0.31% | 0.00% | Jun 2026 |
| Stonehage Fleming Financial Services Holdings Ltd | 89.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 60.00 | 0.00% | 0.00% | Jun 2026 |
| Caitlin John LLC | 35.00 | 0.00% | 0.00% | Jun 2026 |
Psyence Biomedical Ltd. Common Shares company profile
- Company name
- Psyence Biomedical Ltd. Common Shares
- Ticker
- PBM.US
- ISIN
- CA74449F4078
- Exchange
- USA Stocks
- Listed since
- Jan 25, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- March
- Address
- 121 Richmond Street West, Toronto, ON, Canada, M5H 2K1
- Phone
- 416-477-1708
- Website
- psyencebiomed.com
About Psyence Biomedical Ltd. Common Shares
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Psyence Biomedical Ltd. Common Shares management
4- Mr. Jody AufrichtigCo-Founder, Executive Chairman & CEO · born 1974
- Mr. Warwick Ron Corden-LloydCFO & Director · born 1980
- Dr. Neil Maresky M.D.Global Head of Clinical Development · born 1964
- Ms. Taryn VosGeneral Counsel